Sandra Horning was Executive Vice President, Chief Medical Officer and Head of Global Product Development for Roche/Genentech from 2014-2020 and, earlier, was Senior Vice President, Global Head of Oncology Clinical Science from 2009- 2013. She currently serves on the Board of Directors of Gilead Sciences, Moderna, Olema Oncology and Cellarity, and she is a co-founder and Board Member of EQRx.
During her tenure at Genentech/Roche, she oversaw the successful development of 15 new molecular entities (NMEs) with 3 additional filed NMEs, numerous line extensions of marketed products, and 28 FDA Breakthrough Designations in oncology, hematology, neuroscience, ophthalmology, immunology and infectious disease.
In addition to leading the ~5000 person Global Product Development organization and chairing the Late Stage Portfolio Committee, Dr. Horning participated in broad collaborative efforts to accelerate innovative drug development including Breakthrough Designation and complete pathologic response in breast cancer and minimal residual disease in hematologic malignancy as surrogate endpoints.
Dr. Horning served on the Board of Directors of Foundation Medicine from 2015-18. She was recognized as the 2020-1 Healthcare Business Women’s Woman of the Year, a 2018 San Francisco Business Times Women Who Lead in Life Sciences, a 2014 Fierce Biotech Top Woman, recipient of the 2017 University of California San Diego Excellence in Translational Medicine award, and the 25 in 25 recognition from the Friends of Cancer Research in 2022.
Prior to joining Roche/GNE, Dr. Horning was a tenured professor, practicing oncologist and investigator, and held multiple leadership positions including University Fellow, Senator and Vice-Chair of the Department of Medicine at Stanford University, where she is an Emerita Professor of Medicine (Oncology and Blood and Bone Marrow Transplantation). She is a recipient of the Excellence in Patient Care award from the Stanford School of Medicine.
Sandra has authored more than 300 peer-reviewed journal articles, book chapters, reviews and editorials, and has served on the editorial boards of multiple peer-reviewed medical journals. She was named a Best Doctor in America consecutively from 1992-2008, served as a member of FDA’s Oncology Drugs Advisory Committee, Chairman of the Eastern Cooperative Oncology Group lymphoma committee and 2005-6 President of the American Society of Clinical Oncology. She is a fellow of the American Society of Clinical Oncology and a fellow of the American College of Physicians.
Sandra received Bachelor of Arts and Doctor of Medicine degrees at the University of Iowa and completed post-doctoral training in internal medicine at the University of Rochester and in medical oncology at Stanford University.
Recent Comments